著者

Koichi Inoue Tomoyuki Fujita Daisuke Yoshioka Kohei Tonai Yusuke Yanagino Takashi Kakuta Naoki Tadokoro Naonori Kawamoto Kizuku Yamashita Ai Kawamura Ryohei Matsuura Takuji Kawamura Tetsuya Saito Masashi Kawamura Satoshi Kainuma Satsuki Fukushima Koichi Toda Shigeru Miyagawa

出版者

The Japanese Circulation Society

雑誌

Circulation Journal (ISSN:13469843)

巻号頁・発行日

vol.86, no.12, pp.1961-1967, 2022-11-25 (Released:2022-11-25)

参考文献数

21

被引用文献数

2

---

Background: The superiority of a fully magnetically levitated centrifugal-flow left ventricular assist device (LVAD) in terms of overall survival, stroke events and pump thrombosis has been demonstrated in previous international analyses, so we evaluated a Japanese cohort for the same.Methods and Results: This retrospective observational study was conducted at Osaka University Medical Hospital and the National Cerebral and Cardiovascular Center in Japan. A total of 75 consecutive patients who underwent HeartMate3 (HM3) implantation were included. The primary endpoint was on-device survival, and the secondary endpoint was the incidence of LVAD-related complications at 2 years. All parameters were compared with those of the previously performed HeartMate II (HMII) implantation in 197 cases. The on-device survival rates were 94.7% and 92.3% in the HM3 and HMII groups, respectively, at the 2-year follow-up (P=0.62). The rehospitalization-free rate after implantation was 61.8% in the HM3 group, which was significantly higher than that in the HMII group (relative risk, 0.35; 95% confidence interval [CI], 0.23–0.55; P<0.0001). Event-free survival rates from cerebral cerebrovascular events and pump thrombosis in the HM3 group were significantly higher than those in the HMII group, at 97.2% and 100%, respectively (relative risk, 0.14; 95% CI 0.03–0.58); P=0.0015 and relative risk, not calculated; P=0.049, respectively).Conclusions: Satisfactory short-term outcomes were observed after HM3 implantation in a Japanese cohort.